Immunocore Holdings plc (NASDAQ:IMCR) Forecasted to Post Q2 2024 Earnings of ($0.46) Per Share

Immunocore Holdings plc (NASDAQ:IMCRFree Report) – Analysts at Leerink Partnrs cut their Q2 2024 earnings per share estimates for shares of Immunocore in a research note issued on Wednesday, May 8th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.46) per share for the quarter, down from their prior estimate of ($0.41). Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.77) per share. Leerink Partnrs also issued estimates for Immunocore’s Q3 2024 earnings at ($0.56) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($1.90) EPS and FY2025 earnings at ($2.41) EPS.

Other research analysts have also recently issued reports about the company. HC Wainwright increased their price target on Immunocore from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research note on Thursday, May 9th. SVB Leerink assumed coverage on shares of Immunocore in a report on Monday, April 29th. They set an “outperform” rating and a $74.00 target price on the stock. Canaccord Genuity Group upped their price target on shares of Immunocore from $63.00 to $67.00 and gave the company a “hold” rating in a research report on Thursday, May 9th. Finally, JPMorgan Chase & Co. raised their target price on Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.85.

View Our Latest Report on IMCR

Immunocore Price Performance

IMCR stock opened at $56.99 on Monday. Immunocore has a 1 year low of $42.21 and a 1 year high of $76.98. The company has a debt-to-equity ratio of 1.22, a current ratio of 5.96 and a quick ratio of 5.94. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -46.71 and a beta of 0.92. The company has a 50 day simple moving average of $60.27 and a 200 day simple moving average of $61.71.

Immunocore (NASDAQ:IMCRGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12). Immunocore had a negative return on equity of 16.54% and a negative net margin of 22.60%. The business had revenue of $70.30 million for the quarter, compared to analyst estimates of $70.72 million. During the same period in the previous year, the firm posted ($0.35) EPS. The firm’s revenue was up 27.6% compared to the same quarter last year.

Institutional Investors Weigh In On Immunocore

Several large investors have recently added to or reduced their stakes in IMCR. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Immunocore during the 3rd quarter worth approximately $650,000. TD Asset Management Inc boosted its stake in Immunocore by 109.9% during the third quarter. TD Asset Management Inc now owns 301,920 shares of the company’s stock worth $15,670,000 after acquiring an additional 158,086 shares in the last quarter. Assetmark Inc. increased its stake in Immunocore by 54.9% in the third quarter. Assetmark Inc. now owns 11,011 shares of the company’s stock valued at $571,000 after purchasing an additional 3,902 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Immunocore by 1.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 108,651 shares of the company’s stock valued at $5,639,000 after purchasing an additional 1,513 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Immunocore by 103.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock worth $43,000 after purchasing an additional 426 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

(Get Free Report)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Further Reading

Earnings History and Estimates for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.